2003
Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions : implications for management. Am J Clin Dermatol. 2003;4(6):407-28.
Lymphoid malignancies: immunophenotypic analysis. Adv Clin Chem. 2003;37:293-353.
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(16):3051-9.
Images in pathology: Helicobacter heilmannii gastritis. Int J Surg Pathol. 2003;11(4):315.
Interpretative problems and preparative technique influence reliability of intraoperative parathyroid touch imprints. Arch Pathol Lab Med. 2003;127(1):64-7.
The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest. 2003;112(2):170-80.
The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol. 2003;31(8):702-7.
Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 2003;3(3):219-31.
The utility of the in situ detection of T-cell receptor Beta rearrangements in cutaneous T-cell-dominant infiltrates. Diagn Mol Pathol. 2003;12(3):133-41.